Peregrine Capital Management LLC Sells 63,974 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Peregrine Capital Management LLC cut its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 32.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 135,678 shares of the specialty pharmaceutical company’s stock after selling 63,974 shares during the quarter. Peregrine Capital Management LLC’s holdings in Supernus Pharmaceuticals were worth $4,906,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of SUPN. Pacer Advisors Inc. grew its position in Supernus Pharmaceuticals by 29.9% during the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after acquiring an additional 403,028 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in Supernus Pharmaceuticals by 145.7% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,864 shares of the specialty pharmaceutical company’s stock worth $6,699,000 after acquiring an additional 127,420 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in Supernus Pharmaceuticals by 14.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after acquiring an additional 91,354 shares during the last quarter. Geode Capital Management LLC grew its position in Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in Supernus Pharmaceuticals by 40.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after acquiring an additional 73,118 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $57.00 to $36.00 in a report on Wednesday.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $33.52 on Thursday. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The stock has a 50 day simple moving average of $37.58 and a two-hundred day simple moving average of $35.27. The stock has a market cap of $1.85 billion, a P/E ratio of 31.33 and a beta of 0.90.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. This trade represents a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 9.30% of the company’s stock.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.